Scoop: Metagenomi is preparing for an IPO this fall, in what could jumpstart a wave of public offerings
Gene-editing biotech Metagenomi is preparing to go public and is working with the investment bank JP Morgan on a potential listing this fall, according to people familiar with the company’s plans.
If Metagenomi goes public, it would be one of only about a dozen biotech IPOs this year, though likely one of the largest. It has already brought in more than $400 million in venture capital funding and from biopharma partnerships, an amount that puts it in the same class of fundraising as other significant IPOs of 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.